Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28778586 | 0.86 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL10619019 | 0.84 | TSHR (0.60) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL4067424 | 0.84 | TSHR (0.60) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL10515856 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL137704 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL27988824 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL4807396 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL11119285 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| Potassium Ion SCHEMBL10515756 | 0.82 | TSHR (0.58) | TSHRCYP3A4MCOLN3MEN1KMT2A | |
| SCHEMBL15356391 | 0.81 | TSHR (0.56) | TSHRCYP3A4MCOLN3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825611-B | 4(1H) -quinovone derivatives and uses thereof | 刘扶东 | 2022-09-09 | — | — | CN | disclosed |
| CN-114945572-A | HBF pharmacological inducing compounds for the treatment of sickle cell anemia and beta-thalassemia | 刘扶东 | 2022-08-26 | — | — | CN | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| WO-2016044771-A1 | HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-5086128-A | HIGH MOLECULAR WEIGHT ARYLENE SULPHIDE POLYMER MELT MIXED WITH AROMATIC NITRO COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| US-4990523-A | Treatment of chronic inflammatory joint disease with arylsulfonamides | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-02-05 | — | — | US | disclosed |
| WO-1990015600-A2 | TREATMENT OF CHRONIC INFLAMMATORY JOINT DISEASE WITH ARYLSULFONAMIDES | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-27 | — | — | WO | disclosed |
| EP-0345550-A2 | High molecular weight arylene sulphide polymers | BAYER AG (DE) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SLC10A1, HAVCR2, UGT1A3 | TSHR 4285/4885CYP3A4 52/4885MCOLN3 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.